(Q51385645)

4 April 2018

title

Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. (English)

1 reference

4 April 2018

1 reference

E J Hamilton

1

1 reference

4 April 2018

E Gianatti

2

1 reference

4 April 2018

B J Strauss

3

1 reference

4 April 2018

J Wentworth

4

1 reference

4 April 2018

D Lim-Joon

5

1 reference

4 April 2018

D Bolton

6

1 reference

4 April 2018

J D Zajac

7

1 reference

4 April 2018

M Grossmann

8

1 reference

4 April 2018

publication date

1 March 2011

1 reference

4 April 2018

published in

Clinical Endocrinology

1 reference

4 April 2018

volume

74

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

page(s)

377-383

1 reference

4 April 2018

Androgen deprivation therapy for prostate cancer: new concepts and concerns

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Low testosterone levels are common and associated with insulin resistance in men with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Long-term effects of androgen deprivation therapy in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Testosterone and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Testosterone concentrations in diabetic and nondiabetic obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Effects of androgen therapy on adipose tissue and metabolism in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Changes in body composition during androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Late onset of obesity in male androgen receptor-deficient (AR KO) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Sex steroid hormones, upper body obesity, and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2010.03942.X

10.1111/J.1365-2265.2010.03942.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

21118287

1 reference

4 April 2018